Glimepiride is an oral sulfonylurea hypoglycemic drug that mainly works by stimulating pancreatic beta cells to release insulin. This effect is mainly based on increasing the responsiveness of pancreatic beta cells to physiological concentrations of glucose. In addition, glimepiride also has an extrapancreatic hypoglycemic effect. 1. Insulin release: It regulates insulin secretion by closing the ATP-sensitive potassium ion channel of the pancreatic beta cell membrane, inducing beta cell membrane depolarization by closing the potassium ion channel, and opening the calcium ion channel to cause calcium ion influx, promoting insulin release. 2. Extrapancreatic activity: The extrapancreatic effect is to improve the sensitivity of peripheral tissues to insulin, reduce the output of glucose by the liver, increase the number of glucose transfer molecules in the plasma membrane of muscle and fat cells, and thus stimulate glucose uptake. 3. Pharmacodynamic characteristics: The minimum effective oral dose for healthy people is about 0.6 mg, and the effect is dose-dependent and repeatable.

Pharmacological action not specified

Antihistamine, sedative and hypnotic, enhances the effect of antitussive drugs, anti-vertigo, anti-tremor paralysis

This product is a quinolone antibacterial drug that acts on bacterial DNA gyrase to interfere with bacterial DNA synthesis, thereby causing bacterial death. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Serratia, Salmonella typhi, Shigella, Pseudomonas aeruginosa, etc.

As a dopamine precursor, it can pass through the blood-brain barrier and be converted into dopamine in the brain, thus supplementing the insufficient dopamine in the basal ganglia of Parkinson's patients.

Inhibit the decarboxylation reaction of levodopa in extracerebral tissues, reduce the adverse reactions caused by peripheral dopamine, and improve the efficacy of levodopa.